Entropy NeurodynamicsASX: ENP
Also known as: Tryptamine Therapeutics Limited, Tryp Therapeutics
Entropy Neurodynamics Limited (formerly Tryptamine Therapeutics Limited, renamed November 2025; ASX: ENP, OTC: TYPTF) is an Australian clinical-stage company developing psilocin-based therapies for conditions with major unmet need including fibromyalgia, binge eating disorder, and IBS. Its two-pronged strategy uses TRP-8802 (oral psilocybin) to establish clinical proof-of-concept, then advances TRP-8803 (proprietary IV psilocin formulation) for precision dosing. Phase 2a fibromyalgia and BED trials showed strong results; the world's first IV psilocin neuropsychiatric trial (TRP-8803 in BED) dosed its first patient on December 1, 2025 at Swinburne University.
Development Programmes
2TRP-8802 (Oral Psilocybin)
PsilocybinBinge eating disorder / fibromyalgia
Programme Tracker
Eating Disorders
Phase 2a BED (NCT05035927, University of Florida) complete; Phase 2a fibromyalgia complete; IBS programme planned
Milestones
Phase II topline
CompletedActual: Aug 1, 2022
Phase 2a BED first patient results: >80% average reduction in binge eating episodes; no drug-related adverse events (NCT05035927, University of Florida)
Why it matters: TRP-8802 achieved >80% reduction in binge eating episodes — a dramatic effect size for a disorder with limited approved treatments (only lisdexamfetamine). This is the first controlled psilocybin trial in binge eating disorder.
Phase II topline
CompletedActual: Jan 1, 2025
Phase 2a fibromyalgia: improvements in pain severity, sleep, and pain interference in all 5 patients; results published in Frontiers in Pain Research 2025 (NCT05128162, University of Michigan)
Why it matters: Fibromyalgia is one of the most treatment-resistant chronic pain conditions. 100% responder rate in the Phase 2a, with results published in a peer-reviewed journal, is a strong signal for Phase 2b development.
Watch next: Phase 2b fibromyalgia trial design and initiation
Recorded Events
Jan 1, 2025: Phase II topline
Aug 1, 2022: Phase II topline
TRP-8803 (IV Psilocin)
PsilocybinBinge eating disorder (IV psilocin FIH)
Programme Tracker
Eating Disorders
World's first clinical study of IV-infused psilocin; first patient dosed December 2025 at Swinburne University Melbourne; Cohort 1 complete, Cohort 2 enrolling
Milestones
Phase I started
CompletedActual: Dec 1, 2025
First patient dosed in world's first IV psilocin clinical trial (Swinburne University, Melbourne, Australia; ANZCTR registered)
Why it matters: TRP-8803 delivers psilocin (the active metabolite of psilocybin) by IV infusion over 140 minutes, bypassing the variable prodrug conversion step and enabling precise, real-time dose titration. This is the first human data on IV psilocin — critical for understanding the dose-response relationship without oral absorption variability.
Watch next: Cohort 1 safety/tolerability/PK results; Cohort 2 completion; fibromyalgia and IBS extensions
Recorded Events
Dec 1, 2025: Phase I started
Quick Facts
- Type
- Public Biotech
- Ticker
- ASX: ENP
- Lead Stage
- Phase II
- HQ
- Australia, Australia
- Website
- Visit